ID
16703
Description
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: New Anticancer Treatment
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Keywords
Versions (1)
- 8/1/16 8/1/16 -
Uploaded on
August 1, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
New Anticancer Treatment, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
New Anticancer Treatment, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Similar models
New Anticancer Treatment, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C0007131 (UMLS CUI [1,2])
No comments